Trial Profile

A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ferric citrate (Primary) ; Calcium acetate; Sevelamer
Indications Hyperphosphataemia
Focus Registrational; Therapeutic Use
Acronyms PERFECTED
Sponsors Keryx Biopharmaceuticals

Most Recent Events

16 Jun 2025 According to an Averoa media release, the European Commission (EC) has granted marketing authorization for XOANACYL in adult patients with chronic kidney disease (CKD): iron deficiency and elevated serum phosphorus levels (hyperphosphatemia) supported by data from three pivotal clinical trials conducted by Akebia.
24 Sep 2015 Results published in Keryx media release.
24 Jul 2015 Results published in Keryx Biopharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com